Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RiskMAP Guidance Includes Plans For A Website

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states

You may also be interested in...



FDA Science Board To Discuss Pre- And Postmarketing Safety

The scientific advisory panel will discuss the agency's pre- and postmarketing safety programs for drugs and biologics at an April 15 meeting. The group will also discuss good manufacturing practices for vaccines; blood; and cell, tissue and gene products.

FDA Science Board To Discuss Pre- And Postmarketing Safety

The scientific advisory panel will discuss the agency's pre- and postmarketing safety programs for drugs and biologics at an April 15 meeting. The group will also discuss good manufacturing practices for vaccines; blood; and cell, tissue and gene products.

Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals

Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.

Related Content

Topics

UsernamePublicRestriction

Register

PS061830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel